Dr Eleni Efstathiou discusses how the results of PROfound and PROpel have impacted her clinical practice by allowing her to take a personalized and targeted approach utilizing PARP inhibition to treat men with HRR gene-mutated mCRPC.
Sections
Sections
01:15
History of LYNPARZA in prostate cancer
02:32
PROFOUND: Study design and efficacy results
03:17
PROPEL: Study design and efficacy results
04:53
Case study: Patient with mCRPC on LYNPARZA
07:47
Future directions for LYNPARZA in prostate cancer
Redefining cancer care for ovarian patients
Dr Bradley Monk highlights his experience with LYNPARZA, the impact that its had on his patients and the clinical community, as well as future directions.
Approaching care for breast cancer patients
Dr Priyanka Sharma discusses how the results of OlympiAD and OlympiA led to the approval of LYNPARZA for BRCA-associated breast cancers as well as the associated impacts on genetic testing in clinical practice.
Redefining cancer care for ovarian patients
Dr Bradley Monk highlights his experience with LYNPARZA, the impact that its had on his patients and the clinical community, as well as future directions.
Approaching care for breast cancer patients
Dr Priyanka Sharma discusses how the results of OlympiAD and OlympiA led to the approval of LYNPARZA for BRCA-associated breast cancers as well as the associated impacts on genetic testing in clinical practice.
References
- Chastek B, Bunner S, Simmons D, et al. Real world trends in biomarker testing in US advanced ovarian cancer patients. Gynecol Oncol. 2021;162(supp 1): S256-S257.
- Ashworth A. A synthetic lethal therapeutic approach: poly (ADP-ribose) polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785-3790.
- O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60:547-560.
- LYNPARZA® (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.
- Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews®. University of Washington. Updated September 21, 2023. https://www.ncbi.nlm.nih.gov/books/NBK1247/
- Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer. 2008;98(2):502-507.
- Lozano R, Castro E, Aragón IM, et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2021;124:552–563.
- Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D’Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137-1154.
- Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
- American Cancer Society (ACS). Breast Cancer Facts & Figures. 2024. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2022-2024-breast-cancer-fact-figures-acs.pdf
- Mateo J, Seed G, Bertan C, et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2020;130(4):1743-1751.
- Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215-1228.
- Audeh MW, Carmichael J, Penson RT, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245-251.
- Mirza MR, Coleman RL, González-Martín A, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020;31(9):1148-1159.
- Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balmana J. Current systemic treatments for the hereditary cancer syndromes: drug development in light of genomic defects. ASCO Educ Book. 2022. doi:10.1200/EDBK_350232
- Tew WP, Lacchetti C, Kohn EC; PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update . J Clin Oncol. 2022;40(33):3878-3881.
- Tung NM, Zakalik D, Somerfield MR; Hereditary Breast Cancer Guideline Expert Panel. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol. 2021;39(26):2959-2961.
